Show simple item record

Cost–Effectiveness of Helicopter Transport of Stroke Patients for Thrombolysis

dc.contributor.authorSilbergleit, Roberten_US
dc.contributor.authorScott, Phillip A.en_US
dc.contributor.authorLowell, Mark J.en_US
dc.contributor.authorSilbergleit, Richarden_US
dc.date.accessioned2010-06-01T20:20:46Z
dc.date.available2010-06-01T20:20:46Z
dc.date.issued2003-09en_US
dc.identifier.citationSilbergleit, Robert; Scott, Phillip A.; Lowell, Mark J.; Silbergleit, Richard (2003). "Cost–Effectiveness of Helicopter Transport of Stroke Patients for Thrombolysis." Academic Emergency Medicine 10(9): 966-972. <http://hdl.handle.net/2027.42/73463>en_US
dc.identifier.issn1069-6563en_US
dc.identifier.issn1553-2712en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73463
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12957981&dopt=citationen_US
dc.description.abstract: Objectives: Treatment with intravenous (IV) or intra-arterial (IA) thrombolysis in patients with acute ischemic stroke demands careful patient selection and specialized institutional capabilities. Physicians at hospitals without these resources may prefer patient transfer for acute treatment. Helicopter transport for these patients has been described but without analysis of the effects of its additional cost. The authors examined the cost–effectiveness of helicopter transport for patients with acute stroke. Methods: Costs per additional good outcome and per quality-adjusted life-year (QALY) were calculated using a computer model. Input variables included flight, thrombolytic agent, and angiography costs; annual cost per patient for long-term care of symptomatic stroke; percentage of transported patients treated; percentage of patients receiving IV versus IA therapy; discount rate; absolute probability of good outcome; annual mortality with and without treatment; and quality-of-life modifier. Sensitivity analysis was performed. Results: Helicopter transport of acute stroke patients to tertiary care centers for thrombolytic therapy costs $35,000 per additional good outcome and $3,700 per QALY for the reference case. Cost–effectiveness was sensitive to the effectiveness of thrombolysis but minimally sensitive to most other input values. Cost per QALY ranged from $0 to $50,000, as the absolute increase in good outcomes (minimal or no deficit) ranged from 20% to 5%. Cost–effectiveness was not sensitive to ranges of helicopter flight costs or the proportion of flown patients undergoing treatment. Conclusions: This model indicates helicopter transfer of patients with suspected acute ischemic stroke for potential thrombolysis is cost-effective for a wide range of system variables.en_US
dc.format.extent135584 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2003 Society for Academic Emergency Medicineen_US
dc.subject.otherAircraften_US
dc.subject.otherCost–Effectiveness Analysisen_US
dc.subject.otherFibrinolytic Agentsen_US
dc.subject.otherStrokeen_US
dc.titleCost–Effectiveness of Helicopter Transport of Stroke Patients for Thrombolysisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Emergency Medicine and Survival Flight, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherDepartment of Diagnostic Radiology, William Beaumont Hospital, Royal Oak, MI.en_US
dc.identifier.pmid12957981en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73463/1/S1069-6563_03_00316-6.pdf
dc.identifier.doi10.1197/S1069-6563(03)00316-6en_US
dc.identifier.sourceAcademic Emergency Medicineen_US
dc.identifier.citedreference1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581 – 7.en_US
dc.identifier.citedreferencedel Zoppo G, Higashida R, Furlan A, Pessin M, Rowley H, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998; 29: 4 – 11.en_US
dc.identifier.citedreferenceFurlan A, Higashida R, Wechsler L, Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA. 1999; 282: 2003 – 11.en_US
dc.identifier.citedreferenceKothari R, Pancioli A, Liu T, Brott T, Broderick J. Cincinnati Prehospital Stroke Scale: reproducibility and validity. Ann Emerg Med. 1999; 33: 373 – 8.en_US
dc.identifier.citedreferenceMorris DL, Rosamond W, Madden K, Schultz C, Hamilton S. Prehospital and emergency department delays after acute stroke: the Genentech Stroke Presentation Survey. Stroke. 2000; 31: 2585 – 90.en_US
dc.identifier.citedreferenceKothari R, Barsan W, Brott T, Broderick J, Ashbrock S. Frequency and accuracy of prehospital diagnosis of acute stroke. Stroke. 1995; 26: 937 – 41.en_US
dc.identifier.citedreferenceSchroeder EB, Rosamond WD, Morris DL, Evenson KR, Hinn AR. Determinants of use of emergency medical services in a population with stroke symptoms: the Second Delay in Accessing Stroke Healthcare (DASH II) Study. Stroke. 2000; 31: 2591 – 6.en_US
dc.identifier.citedreference8. Rapid identification and treatment of acute stroke. In: NIH Consensus Conference. Crystal City, VA, 1997.en_US
dc.identifier.citedreferenceAlberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA. 2000; 283: 3102 – 9.en_US
dc.identifier.citedreferenceChalela J. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke. Stroke. 1999; 30: 2366 – 8.en_US
dc.identifier.citedreferenceConroy M, Rodriguez S, Kimmel S, Kasner S. Helicopter transfer offers a potential benefit to patients with acute stroke. Stroke. 1999; 30: 2580 – 4.en_US
dc.identifier.citedreferenceGearhart P, Wuerz R, Localio A. Cost-effectiveness analysis of helicopter EMS for trauma patients. Ann Emerg Med. 1997; 30: 500 – 6.en_US
dc.identifier.citedreferenceSilbergleit R, Blumstein H. Revascularization options: implications for critical transport. Acad Emerg Med. 1995; 2: 568 – 9.en_US
dc.identifier.citedreferenceFagan S, Morgenstern L, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998; 50: 883 – 90.en_US
dc.identifier.citedreferenceSiegel J, Weinstein M, Russell L, Gold M. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 1339 – 41.en_US
dc.identifier.citedreferenceHolloway R, Benesch C, Rahilly C, Courtright C. A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke. 1999; 30: 1340 – 9.en_US
dc.identifier.citedreferenceKidwell CS, Starkman S, Eckstein M, Weems K, Saver JL. Identifying stroke in the field: prospective validation of the Los Angeles prehospital stroke screen (LAPSS). Stroke. 2000; 31: 71 – 6.en_US
dc.identifier.citedreferenceDerdeyn C, Powers W. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. Stroke. 1996; 27: 1944 – 50.en_US
dc.identifier.citedreferencePorsdal V, Boysen G. Costs of health care and social services during the first year after ischemic stroke. Int J Technol Assess Health Care. 1999; 15: 573 – 84.en_US
dc.identifier.citedreferenceValenzuela TD, Criss EA, Spaite D, Meislin HW, Wright AL, Clark L. Cost-effectiveness analysis of paramedic emergency medical services in the treatment of prehospital cardiopulmonary arrest. Ann Emerg Med. 1990; 19: 1407 – 11.en_US
dc.identifier.citedreferenceTengs TO, Adams ME, Pliskin JS, et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995; 15: 369 – 90.en_US
dc.identifier.citedreferenceMarler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000; 55: 1649 – 55.en_US
dc.identifier.citedreferenceScott P, Temovsky C, Lawrence K, Gudaitis E, Lowell M. Analysis of Canadian population with potential access to intravenous thrombolysis for acute ischemic stroke. Stroke. 1998; 29: 2304 – 10.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.